Date receipt dossier
Company / Sponsor
International AIDS Vaccine Initiative (IAVI)
Phase
I
Treated organism
Humans
Indication category
Infectious disease
Disease
AIDS
Therapeutic approach
Immunotherapy
Genetic modification
genes for the gag, protease and part of the reverse transcriptase proteins of HIV-1
Method of transfer of nucleic acid of interest
Adeno Associated Virus serotype 2
Administered biological material
Recombinant Adeno Associated Virus D (rep, cap)
Route of administration
Intramuscular
Locations in Belgium
Centre Hospitalier Universitaire St Pierre, Brussels - AZ Stuivenberg,
SGS Biopharma Research Unit - Universitair Ziekenhuis Antwerpen
SGS Biopharma Research Unit - Universitair Ziekenhuis Antwerpen
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
IAVI A001/14E02